TYK Medicines, Inc (HKG:2410)

Market Cap	3.26B -73.3%
Revenue (ttm)	n/a
Net Income	-333.58M
EPS	-0.89
Shares Out	384.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	955,000
Open	8.69
Previous Close	8.48
Day's Range	8.47 - 8.75
52-Week Range	7.99 - 25.75
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 1, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 173
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2410

Financial Performance

Financial numbers in CNY